{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:13:13Z","timestamp":1793211193545,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["No.BY21H250002"],"award-info":[{"award-number":["No.BY21H250002"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Zhejiang Medical and Health Research Fund","award":["2021KY057"],"award-info":[{"award-number":["2021KY057"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Many studies have found that miR-26a-5p plays an essential role in the progression of pathological cardiac hypertrophy, however, there is still no evidence on whether miR-26a-5p is related to the activation of autophagy and NLRP3 inflammasome. And the mechanism of miR-26a-5p and NLRP3 inflammasome aggravating pathological cardiac hypertrophy remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Cardiomyocytes were treated with 200\u00b5M PE to induce cardiac hypertrophy and intervened with 10mM NLRP3 inhibitor INF39. In addition, we also used the MiR-26a-5p mimic and inhibitor to transfect PE-induced cardiac hypertrophy. RT-qPCR and western blotting were used to detect the expressions of miR-26a-5p, NLRP3, ASC and Caspase-1 in each group, and we used \u03b1-SMA immunofluorescence to detect the change of cardiomyocyte area. The expression levels of autophagy proteins LC3, beclin-1 and p62 were detected by western blotting. Finally, we induced the SD rat cardiac hypertrophy model through aortic constriction (TAC) surgery. In the experimental group, rats were intervened with MiR-26a-5p mimic, MiR-26a-5p inhibitor, autophagy inhibitor 3-MA, and autophagy activator Rapamycin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In cell experiments, we observed that the expression of miR-26a-5p was associated with cardiomyocyte hypertrophy and increased surface area. Furthermore, miR-26a-5p facilitated autophagy and activated the NLRP3 inflammasome pathway, which caused changes in the expression of genes and proteins including LC3, beclin-1, p62, ACS, NLRP3, and Caspase-1. We discovered similar outcomes in the TAC rat model, where miR-26a-5p expression corresponded with cardiomyocyte enlargement and fibrosis in the cardiac interstitial and perivascular regions. In conclusion, miR-26a-5p has the potential to regulate autophagy and activate the NLRP3 inflammasome, contributing to the development of cardiomyocyte hypertrophy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study found a relationship between the expression of miR-26a-5p and cardiomyocyte hypertrophy. The mechanism behind this relationship appears to involve the activation of the NLRP3 inflammasome pathway, which is caused by miR-26a-5p promoting autophagy. Targeting the expression of miR-26a-5p, as well as inhibiting the activation of autophagy and the NLRP3 inflammasome pathway, could offer additional treatments for pathological cardiac hypertrophy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-023-03695-w","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T15:02:39Z","timestamp":1704294159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The molecular mechanism of MiR-26a-5p regulates autophagy and activates NLRP3 inflammasome to mediate cardiomyocyte hypertrophy"],"prefix":"10.1186","volume":"24","author":[{"given":"Li-qun","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-feng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-ling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,3]]},"reference":[{"key":"3695_CR1","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.yjmcc.2016.06.001","volume":"97","author":"I SHIMIZU","year":"2016","unstructured":"Shimizu I. Physiological and pathological cardiac hypertrophy [J]. J Mol Cell Cardiol. 2016;97:245\u201362.","journal-title":"J Mol Cell Cardiol"},{"issue":"7","key":"3695_CR2","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00109-019-01790-0","volume":"97","author":"W ADZIKA G K, MACHUKI J O, SHANG","year":"2019","unstructured":"Adzika GK, Machuki JO, SHANG W, et al. Pathological cardiac hypertrophy: the synergy of adenylyl cyclases inhibition in cardiac and immune cells during chronic catecholamine stress [J]. J Mol Med (Berl). 2019;97(7):897\u2013907.","journal-title":"J Mol Med (Berl)"},{"key":"3695_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1146\/annurev-genom-083118-015306","volume":"20","author":"R YOTTI","year":"2019","unstructured":"Yotti R, Seidman CE, Seidman JG. Advances in the genetic basis and Pathogenesis of Sarcomere cardiomyopathies [J]. Annu Rev Genomics Hum Genet. 2019;20:129\u201353.","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"7","key":"3695_CR4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41569-018-0007-y","volume":"15","author":"M NAKAMURA","year":"2018","unstructured":"Nakamura M, Sadoshima J. Mechanisms of physiological and pathological cardiac hypertrophy [J]. Nat Rev Cardiol. 2018;15(7):387\u2013407.","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"3695_CR5","doi-asserted-by":"publisher","first-page":"e12894","DOI":"10.1111\/acel.12894","volume":"18","author":"S CHACAR","year":"2019","unstructured":"Chacar S, Hajal J, Saliba Y, et al. Long-term intake of phenolic compounds attenuates age-related cardiac remodeling [J]. Aging Cell. 2019;18(2):e12894.","journal-title":"Aging Cell"},{"issue":"14","key":"3695_CR6","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1091\/mbc.E18-07-0438","volume":"30","author":"RM STEWART","year":"2019","unstructured":"Stewart RM, Rodriguez EC, King MC. Ablation of SUN2-containing LINC complexes drives cardiac hypertrophy without interstitial fibrosis [J]. Mol Biol Cell. 2019;30(14):1664\u201375.","journal-title":"Mol Biol Cell"},{"key":"3695_CR7","doi-asserted-by":"crossref","unstructured":"Ho MY, Wang CY. Role of Irisin in Myocardial Infarction, Heart Failure, and Cardiac hypertrophy [J]. Cells, 2021;10(8).","DOI":"10.3390\/cells10082103"},{"issue":"4","key":"3695_CR8","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1161\/HYPERTENSIONAHA.120.14752","volume":"76","author":"PL LI","year":"2020","unstructured":"Li PL, Liu H, Chen GP, et al. STEAP3 (six-Transmembrane epithelial Antigen of prostate 3) inhibits pathological cardiac hypertrophy [J]. Hypertension. 2020;76(4):1219\u201330.","journal-title":"Hypertension"},{"key":"3695_CR9","doi-asserted-by":"publisher","first-page":"113967","DOI":"10.1016\/j.biopha.2022.113967","volume":"156","author":"S SHI","year":"2022","unstructured":"Shi S, Jiang P. Therapeutic potentials of modulating autophagy in pathological cardiac hypertrophy [J]. Biomed Pharmacother. 2022;156:113967.","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"3695_CR10","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1161\/CIRCULATIONAHA.121.054827","volume":"144","author":"D ZHAO","year":"2021","unstructured":"Zhao D, Zhong G, Li J, et al. Targeting E3 ubiquitin ligase WWP1 prevents Cardiac Hypertrophy through destabilizing DVL2 via inhibition of K27-Linked ubiquitination [J]. Circulation. 2021;144(9):694\u2013711.","journal-title":"Circulation"},{"key":"3695_CR11","doi-asserted-by":"publisher","first-page":"8151836","DOI":"10.1155\/2019\/8151836","volume":"2019","author":"Z QIU","year":"2019","unstructured":"Qiu Z, He Y, Ming H, et al. Lipopolysaccharide (LPS) aggravates high glucose- and Hypoxia\/Reoxygenation-Induced Injury through activating ROS-Dependent NLRP3 inflammasome-mediated pyroptosis in H9C2 cardiomyocytes. J Diabetes Res. 2019;2019:8151836.","journal-title":"J Diabetes Res"},{"key":"3695_CR12","doi-asserted-by":"crossref","unstructured":"Bai Y, Sun X. Chu Q, Caspase-1 regulate AngII-induced cardiomyocyte hypertrophy via upregulation of IL-1\u03b2 [J]. Biosci Rep, 2018;38(2).","DOI":"10.1042\/BSR20171438"},{"issue":"11","key":"3695_CR13","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1161\/CIRCULATIONAHA.106.643585","volume":"115","author":"M SUN","year":"2007","unstructured":"Sun M, Chen M, Dawood F, et al. Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state [J]. Circulation. 2007;115(11):1398\u2013407.","journal-title":"Circulation"},{"key":"3695_CR14","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3389\/fimmu.2019.00276","volume":"10","author":"Y ZHEN","year":"2019","unstructured":"Zhen Y, Zhang H. NLRP3 inflammasome and inflammatory bowel Disease [J]. Front Immunol. 2019;10:276.","journal-title":"Front Immunol"},{"key":"3695_CR15","doi-asserted-by":"publisher","first-page":"e10371","DOI":"10.7717\/peerj.10371","volume":"8","author":"L TANG","year":"2020","unstructured":"Tang L, Xie J, Yu X, et al. MiR-26a-5p inhibits GSK3\u03b2 expression and promotes cardiac hypertrophy in vitro [J]. PeerJ. 2020;8:e10371.","journal-title":"PeerJ"},{"issue":"1","key":"3695_CR16","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3892\/ijmm.2014.1755","volume":"34","author":"Q XIE","year":"2014","unstructured":"Xie Q, Shen WW, Zhong J, et al. Lipopolysaccharide\/adenosine triphosphate induces IL\u20131\u03b2 and IL-18 secretion through the NLRP3 inflammasome in RAW264.7 murine macrophage cells [J]. Int J Mol Med. 2014;34(1):341\u20139.","journal-title":"Int J Mol Med"},{"issue":"4","key":"3695_CR17","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/imm.13046","volume":"156","author":"S TARTEY","year":"2019","unstructured":"Tartey S, Kanneganti TD. Differential role of the NLRP3 inflammasome in Infection and tumorigenesis [J]. Immunology. 2019;156(4):329\u201338.","journal-title":"Immunology"},{"key":"3695_CR18","doi-asserted-by":"crossref","unstructured":"Minutoli L, Puzzolo D, Rinaldi M et al. ROS-Mediated NLRP3 Inflammasome Activation in Brain, Heart, Kidney, and Testis Ischemia\/Reperfusion Injury [J]. Oxid Med Cell Longev, 2016;2016:2183026.","DOI":"10.1155\/2016\/2183026"},{"issue":"1","key":"3695_CR19","first-page":"172","volume":"44","author":"ZHANG Y Z","year":"2019","unstructured":"Zhang YZ, Sui XL, Xu YP, et al. NLRP3 inflammasome and lipid metabolism analysis based on UPLC-Q-TOF-MS in gouty Nephropathy [J]. Int J Mol Med. 2019;44(1):172\u201384.","journal-title":"Int J Mol Med"},{"issue":"6","key":"3695_CR20","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41589-019-0277-7","volume":"15","author":"RC COLL","year":"2019","unstructured":"Coll RC, Hill JR, Day CJ, et al. MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition [J]. Nat Chem Biol. 2019;15(6):556\u20139.","journal-title":"Nat Chem Biol"},{"issue":"10","key":"3695_CR21","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/nri3532","volume":"13","author":"V DERETIC","year":"2013","unstructured":"Deretic V, Saitoh T. Autophagy in Infection, inflammation and immunity [J]. Nat Rev Immunol. 2013;13(10):722\u201337.","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"3695_CR22","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1080\/15548627.2019.1596481","volume":"15","author":"X HAN","year":"2019","unstructured":"Han X, Sun S, Sun Y, et al. Small molecule-driven NLRP3 inflammation inhibition via interplay between ubiquitination and autophagy: implications for Parkinson Disease [J]. Autophagy. 2019;15(11):1860\u201381.","journal-title":"Autophagy"},{"key":"3695_CR23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.molimm.2017.02.013","volume":"86","author":"J HARRIS","year":"2017","unstructured":"Harris J, Lang T, Thomas JP W, et al. Autophagy and inflammasomes [J]. Mol Immunol. 2017;86:10\u20135.","journal-title":"Mol Immunol"},{"key":"3695_CR24","doi-asserted-by":"crossref","unstructured":"Tao Y, Wang N, Qiu T et al. The Role of Autophagy and NLRP3 Inflammasome in Liver Fibrosis [J]. Biomed Res Int, 2020;2020:7269150.","DOI":"10.1155\/2020\/7269150"},{"key":"3695_CR25","doi-asserted-by":"publisher","first-page":"591803","DOI":"10.3389\/fimmu.2020.591803","volume":"11","author":"M BIASIZZO","year":"2020","unstructured":"Biasizzo M, Kopitar-Jerala N. Interplay between NLRP3 inflammasome and autophagy [J]. Front Immunol. 2020;11:591803.","journal-title":"Front Immunol"},{"issue":"12","key":"3695_CR26","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1161\/CIRCRESAHA.121.318908","volume":"129","author":"L QIAO","year":"2021","unstructured":"Qiao L, Ma J, Zhang Z, et al. Deficient chaperone-mediated Autophagy promotes inflammation and Atherosclerosis [J]. Circ Res. 2021;129(12):1141\u201357.","journal-title":"Circ Res"},{"issue":"3","key":"3695_CR27","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.bbadis.2017.12.027","volume":"1864","author":"P LIU","year":"2018","unstructured":"Liu P, Huang G, Wei T, et al. Sirtuin 3-induced macrophage autophagy in regulating NLRP3 inflammasome activation [J]. Biochim Biophys Acta Mol Basis Dis. 2018;1864(3):764\u201377.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"7","key":"3695_CR28","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1002\/jcp.24903","volume":"230","author":"CHANG Y P","year":"2015","unstructured":"Chang YP, Ka SM, Hsu WH, et al. Resveratrol inhibits NLRP3 inflammasome activation by preserving mitochondrial integrity and augmenting autophagy [J]. J Cell Physiol. 2015;230(7):1567\u201379.","journal-title":"J Cell Physiol"},{"key":"3695_CR29","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.biopha.2017.03.003","volume":"89","author":"H ZHOU","year":"2017","unstructured":"Zhou H, Feng L, Xu F, et al. Berberine inhibits palmitate-induced NLRP3 inflammasome activation by triggering autophagy in macrophages: a new mechanism linking berberine to insulin resistance improvement [J]. Biomed Pharmacother. 2017;89:864\u201374.","journal-title":"Biomed Pharmacother"},{"issue":"23","key":"3695_CR30","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.1038\/emboj.2011.398","volume":"30","author":"N DUPONT","year":"2011","unstructured":"Dupont N, Jiang S, Pilli M, et al. Autophagy-based unconventional secretory pathway for extracellular delivery of IL-1\u03b2 [J]. Embo j. 2011;30(23):4701\u201311.","journal-title":"Embo j"},{"key":"3695_CR31","doi-asserted-by":"crossref","unstructured":"Wu M Y, LU JH. Autophagy and macrophage functions: inflammatory response and phagocytosis [J]. Cells, 2019;9(1).","DOI":"10.3390\/cells9010070"},{"issue":"1","key":"3695_CR32","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1038\/s41467-021-23923-1","volume":"12","author":"F HU","year":"2021","unstructured":"Hu F, Song D, Yan Y, et al. IL-6 regulates autophagy and chemotherapy resistance by promoting BECN1 phosphorylation [J]. Nat Commun. 2021;12(1):3651.","journal-title":"Nat Commun"},{"issue":"1","key":"3695_CR33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12943-019-0944-z","volume":"18","author":"GM JIANG","year":"2019","unstructured":"Jiang GM, Tan Y, Wang H, et al. The relationship between autophagy and the immune system and its applications for Tumor immunotherapy [J]. Mol Cancer. 2019;18(1):17.","journal-title":"Mol Cancer"},{"issue":"5","key":"3695_CR34","doi-asserted-by":"publisher","first-page":"e1258","DOI":"10.1002\/ctm2.1258","volume":"13","author":"X CHENG","year":"2023","unstructured":"Cheng X, Xing Jiand. Circulating cardiac MicroRNAs safeguard against dilated cardiomyopathy [J]. Clin Transl Med. 2023;13(5):e1258.","journal-title":"Clin Transl Med"},{"key":"3695_CR35","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ijcard.2021.11.004","volume":"347","author":"P PFEIFER","year":"2022","unstructured":"Pfeifer P, Zietzer A, H\u00f6lscher M, et al. Transverse aortic constriction-induced Heart Failure leads to increased levels of circulating microparticles [J]. Int J Cardiol. 2022;347:54\u20138.","journal-title":"Int J Cardiol"},{"issue":"11","key":"3695_CR36","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1002\/cbin.11685","volume":"45","author":"H SHI","year":"2021","unstructured":"Shi H, Li H, Zhang F, et al. MiR-26a-5p alleviates cardiac hypertrophy and dysfunction via targeting ADAM17 [J]. Cell Biol Int. 2021;45(11):2357\u201367.","journal-title":"Cell Biol Int"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-023-03695-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-023-03695-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-023-03695-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T15:05:54Z","timestamp":1704294354000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-023-03695-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,3]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3695"],"URL":"https:\/\/doi.org\/10.1186\/s12872-023-03695-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3108457\/v1","asserted-by":"object"}]},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,3]]},"assertion":[{"value":"26 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study approval statement:This study protocol was reviewed and approved by [Experimental Animal Welfare and Ethics Committee of Zhejiang Academy of Agricultural Sciences], approval number [2021ZAASLA46]. All methods were carried out in accordance with relevant guidelines and regulations, and all methods were reported in accordance with ARRIVE guidelines for the reporting of animal experiments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}